Synthesis and cyclic GMP phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d]pyrimidones

Journal of Medicinal Chemistry

Volumn 39, Issue 8, 1996, Pages 1635-1644

  Dumaître, Bernard ^a   Dodic, Nerina ^a  

^a Laboratoire GlaxoWellcome   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYL 1,5 DIHYDRO 3 METHYL 6 [2 PROPOXY 5 (4 METHYL 2 THIAZOLYL)PHENYL]PYRAZOLO[3,4 D]PYRIMIDIN 4 ONE; 1,5 DIHYDRO 1,3 DIMETHYL 6 (2 PROPOXY 5 METHANESULFONAMIDOPHENYL)PYRAZOLO[3,4 D]PYRIMIDIN 4 ONE; 2 (2 PROPOXYPHENYL)HYPOXANTHINE; CYCLIC GMP PHOSPHODIESTERASE INHIBITOR; PYRAZOLO[3,4 B]PYRIDINE DERIVATIVE; SKF 96231; UNCLASSIFIED DRUG; ZAPRINAST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONGESTIVE HEART FAILURE; DIURESIS; DOSE RESPONSE; DRUG MECHANISM; DRUG STABILITY; DRUG SYNTHESIS; HYPERTENSION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION; VASODILATATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; ENZYME INHIBITORS; HUMANS; PYRIMIDINONES; RATS; RATS, INBRED SHR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029966284     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950812j     Document Type: Article

References (15)

1. Beavo, J. A.; Reifsnyder, D. H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. 1990, 11, 150-155.
2. Erhardt, P. W. Second generation phosphodiesterase inhibitors; structure-activity relationships and receptor models. Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action; John Wiley and Sons Ltd.: New York, 1990; pp 317-332
3. Yasutaka, T.; Takao, S.; Masatoshi, P.; Isao, S. Cyclic GMP Phosphodiesterase Inhibitors. 1. The discovery of a novel potent inhibitor, 4-(3.,-(methylenedioxybenzyl)amino)-6,7,8-trimethoxyquinazoline. J. Med. Chem. 1993, 36, 3765-3770.
4. Tremblay, J.; Gerrer, R.; Hamet, P. Cyclic GMP in cell function. Adv Second Messenger Phosphoprotein Res. 1988, 22, 319-383.
5. Waldman, M.; Murad, F. Cyclic GMP, synthesis and function. Pharmacol. Rev. 1987, 39, 163-196.
6. Lincoln, T. M. Cyclic GMP and mechanisms of vasodilatation. Pharmacol. Ther. 1989, 41, 479-502.
7. Nicholson, C.; Challis, R.; Shakio. M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends. Pharmacol. Sci. 1991, 12, 19-27.
8. Coates, W. J. Eur. Pat. EP32960, 1990; Chem. Abstr. 1990, 113, 40713.
9. Coates, W. J. Eur. Pat. EP351058, 1990; Chem Abstr. 1990, 113, 40711.
10. Hamilton, H. W.; Ortwine, D. F.; Worth, D. F.; Bristol, J. A. Synthesis and Structure-Activity Relationships of pyrazolo[4,3-d]pyrimidin-7-ones as Adenosine Receptor antagonists. J. Med. Chem. 1987, 30, 91-96.
11. Bell, A. S.; Terret, N. K. PCTApp WO93/07149, 1993.
12. Terret, N. K. PCTApp WO94/00453, 1994.
13. Wells, J. N.; Baird, C. E.; Wu, Y. J.; Hardmann, J. G. Cyclic nucleotide phosphodiesterase activities of pig coronary arteries. Biochim. Biophys. Acta 1975, 384, 430-442.
14. Chamley, J. H.; Campbell, G. R.; MeConnel, J. D ; Groschel, S. U. Comparison of vascular smooth muscle cells from adult human, monkey and rabbit in primary culture and in subculture. Cell Tissue Res. 1977, 177, 503-522.
15. Coste, H.; Grondin, P. Characterisation of a novel potent and specific inhibitor of type V phosphodiesterase. Biochem. Pharmacol. 1995, 50, 1577-1585.